Maho Aoyama1, Kento Masukawa2, Ikuko Sugiyama2, Tatsuya Morita3, Yoshiyuki Kizawa4, Satoru Tsuneto5, Yasuo Shima6, Mitsunori Miyashita2. 1. Department of Palliative Nursing, Health Sciences, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan. mahot-wmh@med.tohoku.ac.jp. 2. Department of Palliative Nursing, Health Sciences, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan. 3. Palliative Care Team, Department of Palliative and Supportive Care, Seirei Mikatahara General Hospital, 3453 Mikatahara-cho, Kita-ku, Hamamtsu, Shizuoka, 433-8558, Japan. 4. Center for Pallitive and Supportive Care, University of Tsukuba Hospital, 2-1-1, Amakubo, Tsukuba, Ibaraki, 305-8576, Japan. 5. Department of Human Health Sciences, Kyoto University Graduate School of Medicine, 54 Kawaharacho, Shogoin, Saikyo-ku, Kyoto, 606-8507, Japan. 6. Tsukuba Medical Center Foundation, Home Care Service, Department of Palliative Medicine, Tsukuba Medical Center Hospital, 1-3-1, Amakubo, Tsukuba, Ibaraki, 305-8558, Japan.
Abstract
PURPOSE: No studies have investigated the association between malignant brain tumor and the quality of dying, which is an important outcome in end-of-life care. This study aimed to clarify whether the quality of dying and related factors in patients with malignant brain tumor differ from those in patients with other malignant diseases. METHODS: This was a secondary analysis of data collected by two nationwide, multicenter, bereavement surveys of palliative care units in Japan. This analysis included 14,171 bereaved family members (160 patients with malignant brain tumors). The quality of dying was examined using the good death inventory (GDI), a validated tool widely used in palliative care settings. RESULTS: Patients with malignant brain tumors were younger (p < 0.0001) and had a longer palliative care unit stay during their end-of-life (p < 0.0001) than others. The total GDI score was significantly lower in patients with malignant brain tumors than others (p < 0.0001). Five GDI items were significantly lower in the malignant brain tumor group than other cancer group: "Being able to stay in one's favorite place" (p = 0.03); "Trusting the physician" (p = 0.003); "Not being a burden to others" (p = 0.01); "Being independent in daily activities" (p = 0.01); and "Feeling that one's life is worth living" (p = 0.001). CONCLUSION: This study showed that the quality of dying of patients with malignant brain tumors was lower compared to other cancers, suggesting the need to review care for patients with malignant brain tumors based on their characteristics.
PURPOSE: No studies have investigated the association between malignant brain tumor and the quality of dying, which is an important outcome in end-of-life care. This study aimed to clarify whether the quality of dying and related factors in patients with malignant brain tumor differ from those in patients with other malignant diseases. METHODS: This was a secondary analysis of data collected by two nationwide, multicenter, bereavement surveys of palliative care units in Japan. This analysis included 14,171 bereaved family members (160 patients with malignant brain tumors). The quality of dying was examined using the good death inventory (GDI), a validated tool widely used in palliative care settings. RESULTS: Patients with malignant brain tumors were younger (p < 0.0001) and had a longer palliative care unit stay during their end-of-life (p < 0.0001) than others. The total GDI score was significantly lower in patients with malignant brain tumors than others (p < 0.0001). Five GDI items were significantly lower in the malignant brain tumor group than other cancer group: "Being able to stay in one's favorite place" (p = 0.03); "Trusting the physician" (p = 0.003); "Not being a burden to others" (p = 0.01); "Being independent in daily activities" (p = 0.01); and "Feeling that one's life is worth living" (p = 0.001). CONCLUSION: This study showed that the quality of dying of patients with malignant brain tumors was lower compared to other cancers, suggesting the need to review care for patients with malignant brain tumors based on their characteristics.
Authors: Andrea Pace; Linda Dirven; Johan A F Koekkoek; Heidrun Golla; Jane Fleming; Roberta Rudà; Christine Marosi; Emilie Le Rhun; Robin Grant; Kathy Oliver; Ingela Oberg; Helen J Bulbeck; Alasdair G Rooney; Roger Henriksson; H Roeline W Pasman; Stefan Oberndorfer; Michael Weller; Martin J B Taphoorn Journal: Lancet Oncol Date: 2017-06 Impact factor: 54.433
Authors: Marissa Barbaro; Craig D Blinderman; Fabio M Iwamoto; Teri N Kreisl; Mary R Welch; Yazmin Odia; Laura E Donovan; Adela E Joanta-Gomez; Katharine A Evans; Andrew B Lassman Journal: Neurology Date: 2021-11-18 Impact factor: 9.910